Clinical Trial Update: IBI343 in Combination Therapy for Advanced Malignant Solid Tumors [Phase 2]

View source ↗

Summary

This is a Phase 2 clinical trial update for IBI343 in combination therapy targeting CLDN18.2-positive advanced solid tumors, including gastric cancer and pancre…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Cancer
• Gastroesophageal Junction Adenocarcinoma
• Pancreatic Ductal Adenocarcinoma

Drugs mentioned

• IBI343

Snippet

Sponsor: Innovent Biologics (Suzhou) Co. Ltd. | Conditions: CLDN18.2 Positive, Gastric/Gastroesophageal Junction Adenocarcinoma | Phase 2 | Status: NOT_YET_RECRUITING